ADAGENE INC. - ADS EACH REPRESENTING 1.25 ORDINAR

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

30 авг 2022 17:25:00 Источник Nasdaq GlobeNewswire

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

29 июн 2022 16:05:00 Источник Nasdaq GlobeNewswire

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

26 май 2022 17:00:00 Источник Nasdaq GlobeNewswire

Adagene to Participate in Investor Conferences in May and June

12 май 2022 07:00:02 Источник Nasdaq GlobeNewswire

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

08 апр 2022 13:09:40 Источник Nasdaq GlobeNewswire

Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

31 мар 2022 08:30:00 Источник Nasdaq GlobeNewswire

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

16 мар 2022 07:00:00 Источник Nasdaq GlobeNewswire

Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

08 мар 2022 17:28:17 Источник Nasdaq GlobeNewswire

Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

02 мар 2022 06:00:00 Источник Nasdaq GlobeNewswire

Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

08 фев 2022 07:00:02 Источник Nasdaq GlobeNewswire

Adagene Announces Board and Management Appointments to Support Pipeline Growth

02 фев 2022 16:05:00 Источник Nasdaq GlobeNewswire

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

27 янв 2022 07:00:00 Источник Nasdaq GlobeNewswire

Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

19 янв 2022 07:00:00 Источник Nasdaq GlobeNewswire

Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

13 янв 2022 04:00:00 Источник Nasdaq GlobeNewswire

Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates

22 дек 2021 16:05:00 Источник Nasdaq GlobeNewswire

Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody™

13 дек 2021 10:23:10 Источник Nasdaq GlobeNewswire

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

06 дек 2021 13:49:44 Источник Nasdaq GlobeNewswire

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

06 дек 2021 06:30:00 Источник Nasdaq GlobeNewswire

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

29 ноя 2021 16:05:00 Источник Nasdaq GlobeNewswire

Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021

22 ноя 2021 17:05:50 Источник Nasdaq GlobeNewswire